Becton Dickinson (BDX) Stock Overview
Develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
BDX Community Fair Values
Create NarrativeSee what 30 others think this stock is worth. Follow their fair value or set your own to get alerts.
Becton, Dickinson and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$195.00 |
| 52 Week High | US$251.99 |
| 52 Week Low | US$163.33 |
| Beta | 0.22 |
| 1 Month Change | 9.36% |
| 3 Month Change | 11.17% |
| 1 Year Change | -16.67% |
| 3 Year Change | -26.06% |
| 5 Year Change | -24.69% |
| Change since IPO | 7,505.95% |
Recent News & Updates
Recent updates
Becton, Dickinson and Company: A Solid Divestment For Its Bioscience And Diagnostics Business
Jul 15Becton, Dickinson and Company: It's Wait And See For Me
Apr 27Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline
Mar 30Beckton, Dickinson: Hold, Momentum Is Gaining, Just Need More Growth
Jan 20Statutory Profit Doesn't Reflect How Good Becton Dickinson's (NYSE:BDX) Earnings Are
Dec 04
Becton, Dickinson and Company Q4: Shifting To High-Growth Areas
Nov 12Are Becton, Dickinson and Company (NYSE:BDX) Investors Paying Above The Intrinsic Value?
Oct 22Here's Why Becton Dickinson (NYSE:BDX) Can Manage Its Debt Responsibly
Sep 30Becton, Dickinson and Company: Future Benefit From GLP-1 Drug Delivery
Sep 13Becton, Dickinson And Company: Somewhat Undervalued, A Very Moderate Buy
Aug 06Becton, Dickinson and Company: Stagnating All Along
May 16Becton, Dickinson: 4 Reasons To Buy This Growth At A Reasonable Price Play
Jan 22Shareholder Returns
| BDX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 3.9% | 1.2% | 1.6% |
| 1Y | -16.7% | 6.1% | 17.4% |
Return vs Industry: BDX underperformed the US Medical Equipment industry which returned 6.1% over the past year.
Return vs Market: BDX underperformed the US Market which returned 17.4% over the past year.
Price Volatility
| BDX volatility | |
|---|---|
| BDX Average Weekly Movement | 3.7% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BDX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BDX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 74,000 | Tom Polen | www.bd.com |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.
Becton, Dickinson and Company Fundamentals Summary
| BDX fundamental statistics | |
|---|---|
| Market cap | US$56.17b |
| Earnings (TTM) | US$1.59b |
| Revenue (TTM) | US$21.39b |
Is BDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BDX income statement (TTM) | |
|---|---|
| Revenue | US$21.39b |
| Cost of Revenue | US$11.30b |
| Gross Profit | US$10.09b |
| Other Expenses | US$8.50b |
| Earnings | US$1.59b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 06, 2025
| Earnings per share (EPS) | 5.53 |
| Gross Margin | 47.16% |
| Net Profit Margin | 7.41% |
| Debt/Equity Ratio | 75.9% |
How did BDX perform over the long term?
See historical performance and comparisonDividends
Does BDX pay a reliable dividends?
See BDX dividend history and benchmarks| Becton Dickinson dividend dates | |
|---|---|
| Ex Dividend Date | Sep 08 2025 |
| Dividend Pay Date | Sep 30 2025 |
| Days until Ex dividend | 24 days |
| Days until Dividend pay date | 46 days |
Does BDX pay a reliable dividends?
See BDX dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/14 11:25 |
| End of Day Share Price | 2025/08/14 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Becton, Dickinson and Company is covered by 42 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Adam Feinstein | Barclays |